Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.

Also called NCT01838850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (enrolled count) (from the registry)
Sponsor
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company (from the registry)
Registry
  • NCT NCT01838850
Other papers using this trial's data
  • Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016-04 DOI, PubMed 26691333, PMC4819539 PubMed links an erratum for this paper. Erratum: PMID 26994003 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01838850. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
Condition
Essential Hypertension
Intervention (Drug)
CS8635 20/5/12.5mg and placebo
Intervention (Drug)
Olmetec® Plus 20/12.5mg and placebo
Lead sponsor
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct01838850
Content hash
4f96aac04c2a214bbac5a86fa1585711ace232012bb56b9160c8bbc1f8f8b71c